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Abstract It has remained unclear whether the amount of
fecal fat excreted in the stool and stool production
influences the severity of neonatal jaundice. We deter-
mined the relationship between stool production, fecal fat
excretion and jaundice in healthy breast-fed (BF) or
formula-fed (FF) (near-)term neonates. From postnatal
day 1–4, we quantitatively collected stools from 27 FF
and 33 BF infants in daily fractions. Stool production
and fecal fat contents were related to unconjugated
bilirubin (UCB) levels, as determined by transcutaneous
bilirubinometry (TcB). Bilirubin concentrations and stool
production did not differ between FF and BF neonates
during the study period. Neonatal bilirubin levels were
not inversely correlated with stool production. FF and BF
infants had similar fecal fat excretion rates. The stool
production of FF infants was profoundly lower in the
present study than in a 1985 study by De Carvalho et al.
[J Pediatr (1985) 107:786–790]. We conclude that
increased jaundice during the first postnatal days in
healthy term neonates can no longer be attributed to
breast-feeding and speculate that improved absorbability
of formulas since 1985 has contributed to similar fat
excretion and stool production in FF and BF neonates
in 2007.
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Abbreviations
BF breast-fed
FF formula-fed
TcB transcutaneous bilirubinometry
UCB unconjugated bilirubin
Introduction
Neonatal jaundice is characterized by the accumulation of
unconjugated bilirubin (UCB). UCB mainly originates from
heme degradation in the reticulo-endothelial system and is
transported to the liver for conjugation and subsequent
biliary secretion. In neonates, hepatic conjugation activity is
still low, whereas bilirubin production is transiently
increased.
Breast-feeding has been associated on the one hand with
an exaggeration of neonatal jaundice during the first
postnatal days and, on the other hand, with a prolongation
of the visible jaundice beyond the first 2 weeks of life
(“breast-milk jaundice”)[ 10, 12, 19, 24, 32]. The path-
ophysiology of increased neonatal jaundice in the first
postnatal days in breast-fed (BF) infants has been a matter
of debate. Weight loss in breast-fed infants is frequently
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e-mail: h.j.verkade@bkk.umcg.nlhigher than in formula-fed (FF) infants [19]. However, the
difference in weight loss does not completely correspond to
thehigherincidenceofjaundiceduringbreastfeeding[1, 4, 6].
Gourley and Arend suggested that the presence of
β-glucuronidase in human breast milk – but not in formula
milk – enhances the enterohepatic circulation of bilirubin
[13], but subsequent studies failed to support this hypothesis
[2, 17]. Increased bilirubin absorption, rather than higher
bilirubin production, has been suggested as an alternative
mechanism underlying the exaggeration of breast milk
jaundice [2, 3, 11, 16].
UCB can spontaneously diffuse through lipid bilayers
and hepatocyt membranes [35]. Lester and Schmid and,
more recently, Kotal et al. demonstrated that UCB can enter
the intestinal lumen via biliary secretion and via trans-
epithelial transport in Gunn rats and Crigler Najjar patients,
both known to have persistent unconjugated hyperbiliru-
binemia [20–22]. We recently hypothesized that the
neonatal disposal of UCB from the body is related to the
amount of fat excreted via the feces [33]. According to this
hypothesis, UCB associates with unabsorbed dietary fat in
the intestinal lumen, which prevents its reabsorption
(intestinal capture). The highly efficient fat absorption in
BF infants compared with FF infants [34] may limit the
disposal of UCB in the former and thus contribute to
exaggerate neonatal hyperbilirubinemia. Subsequent studies
in Gunn rats with spontaneous unconjugated hyperbilirubi-
nemia supported the hypothesis. The stimulation of fecal fat
excretion by treating Gunn rats with the lipase inhibitor
orlistat increased fecal UCB excretion and decreased
plasma UCB concentrations [15, 26].
No information is available on the relationship between
neonatal jaundice and fecal fat excretion during the first
postnatal days in infants. De Carvalho et al. demonstrated
that in comparison to FF infants, BF infants had a lower
stool production and fecal bilirubin output and higher
serum bilirubin levels during the first 3 days of life [7].
Similarly, Gourley et al. reported a negative relationship
between stool production and bilirubin levels in healthy
term infants during the first 3 weeks of life [14]. Stool fat
contents, however, were not quantified in these studies.
Thus, these researchers were unable to infer whether the
observed differences were actually due to lower fecal fat
loss in BF infants.
The aim of the present prospective study was to determine
the relationship between bilirubin concentrations, stool
production and fecal fat excretion during the first postnatal
days in healthy term BF and FF neonates. According to our
hypothesis [33], lower fecal fat excretion rates would result
in less fecal excretion of bilirubin and therefor higher levels
of transcutaneously measured bilirubin. To allow compar-
ison with previous data, the present study design closely
mimicked that of De Carvalho et al. [7].
Subjects and methods
Subjects
The study protocol, based on informed parental consent,
was approved by the Medical Ethics Committee of the
Martini Hospital, The Netherlands. The BF group was
breast-fed at least 75% of the daily ingested volume
distributed over six to eight feedings daily. Data from
infants whose total daily intake on any one of the first 5
postnatal days comprised between 25 and 75% formula
milk were not included in the study. The fat composition of
the formula was (per 100 g fatty acids) 38.3 g saturated
fatty acids, 49.3 g monosaturated fatty acids and 12.4 g
polyunsaturated fatty acids. The formula contained 20 g
palmitic acid (C 16:0) per 100 g fatty acids.
Study design
Upon receiving parental consent, infants were enrolled
immediately after birth. Inclusion criteria were gestational
age of at least 36 weeks, Apgar score at 5 min of at least 7,
uncomplicated delivery, either spontaneously or via cesar-
ean section, and an expected stay in the hospital of at least
3 days. Neonates with meconium-stained amniotic fluid,
polycythemia (defined as hematocrit above 0.60), positive
Coombs-test, born by instrumental delivery, any apparent
illness (including symptoms possibly due to infection) or
use of medication were excluded. Maternal characteristics
(parity, pre-existent morbidity), infant characteristics
(Apgar score, sex, race, birth weight) were obtained and
weight was recorded daily.
Methods
The extent of jaundice was measured daily at the same time
in the morning using transcutaneous bilirubinometry (TcB;
BiliCheck, SpectRx, Norgross, Ga.). Each measurement
consisted of placing the BiliCheck on the forehead for three
times, after which the device calculated the average. The
results were related to the post-partum age in hours at the
time of measurement. During the study, transcutaneous
bilirubin values were not used for clinical patient care.
From 48 of the 60 included patients (27 BF, 21 FF) all
stools were quantitatively collected from birth until dis-
charge using inlayer sheets in diapers. During the study
period, fat-containing cream or lotion was avoided at the
diaper area. Soiled inlayer sheets were pooled per day and
frozen at −20°C until analysis. Stool samples were treated
according to the extraction procedure described by Jakobs
et al. [18] with minor modifications. The total weight of the
stools from 1 day was calculated by subtracting the weight
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inlayer sheets per day was analyzed by mixing the stool
with (per gram of stool) with 5 ml of water, 1 ml of HCl
(37%) and 12 ml of ethanol (96%) in a 1-l plastic
container. The mixture was vigorously shaken for 8 min
using a paint container shaker (Minimix Mk3; Merris
Development Engineers, Maidenhead, Berkshire, UK). A
10-g sample of the suspension was put into a Teflon tube
after which 10 ml petroleum ether was added. The tube was
vigorously shaken for 10 min, followed by centrifugation
for 10 min at 800 g, 10°C. A 5-ml portion of the organic
layer was transferred to a glass tube and evaporated for
30 min at 40°C under a stream of nitrogen. The dried lipid
extracts were dissolved in 1.0 ml of chloroform (gradient
grade) and transferred to a transmission flow cell (path
length: 0.025 mm) with sodium chloride crystals.
Spectra were measured in the mid-infrared region (4000–
1300cm
−1). Ten scans were co-added at an optical resolution
of 4 cm
−1 using a Perkin–Elmer Spectrum 1000 Series
Fourier Transform Infrared spectrometer (Perkin–Elmer,
Norfolk Conn.). Chloroform was used for background
subtraction. A primary standard mixture of stearic and
palmitic acids (65:35) was used for the calibration curve in
the range of 0–15 g% using single linear regression analysis
(Beer’s Law). The primary standards were handled in the
same way as the fecal samples. From the three characteristic
peaks in the spectrum (2927, 2855 and 1709 cm
−1), the
heights at 2855 cm
−1 was used for calculation.
Statistics
All results are presented as means ± standard error of the
mean. Differences between FF and BF neonates were
evaluated by the Student’s t-test or, in absence of a normal
distribution, the Mann Whitney U-test. Correlations be-
tween parameters were calculated using Pearson rank
correlation coefficient. The level of significance was set at
p<0.05. The analysis was performed using SPSS ver. 10 for
Windows software (SPSS, Chicago, Ill.).
Results
Table 1 shows the characteristics of the BF and FF infants
studied. Thirty-three BF and 27 FF (Nutrilon Premium)
infants were studied during the first postnatal days (4±1
days, mean ± SEM). FF infants received at least 75% of the
daily volume intake as formula-feeding. Initially, 64 infants
had been included, but the results of four infants were not
used for the analyses because of incomplete data (n=2),
discharge on the second postnatal day (n=1) or severe
hyperbilirubinemia requiring phototherapy on the second
postnatal day (n=1). Of the remaining 60 infants (gesta-
tional age: 39.2±0.2 weeks), one FF infant developed
hyperbilirubinemia at day 4 and was treated with photo-
therapy. The data of this infant were included in the
analysis until the start of phototherapy. The two groups did
not differ significantly in birth weight, gestational age,
male/female distribution or delivery via caesarean section
(Table 1). The rate of cesarean section is high, attributable
to the inclusion criterium of healthy (near-)term infants
with an expected stay in the hospital of at least 3 days. The
fraction of first-borns was higher in the BF group than in
the FF group (67 vs. 23%, respectively). BF infants lost
significantly more weight than FF infants during the study
period (p=0.013; Table 1).
Figure 1 shows that the TcB values were very similar in
the BF and FF group during the first 4 postnatal days.
Maximum bilirubin levels during the study period were
reached at the fourth day: 153±10 and 146±10 μmol/l in
BF and FF infants, respectively. Levels in the BF group
seemed to level off at day 4, in contrast to the FF group. No
significant differences in TcB were found between BF and
FF infants on any of the study days. Although BF infants
lost more bodyweight, neonatal weight loss was not
significantly related to TcB levels in either group (FF;
r
2=0.01, BF; r
2=0.05).
Figure 2 shows that the stool production was similar
between the BF and FF infants on any one of the days.
Cumulative fecal weight in the first 4 postnatal days was
4 9 ± 4gi nB Fi n f a n t sa n d4 6 ± 4gi nF Fi n f a n t s ,a
non-significant difference. Figure 3 shows the cumulative
fecal fat excretion in the two groups. Between birth and
postnatal day 4, BF infants had a cumulative fecal fat
excretion of 3.2±0.7 g, which was similar to the 3.9±1.3 g
excreted by FF infants.
Table 1 Characteristics of the breast-fed and formula-fed group of
infants
Breast-fed
infants
Formula-fed
infants
n 33 27
Birth weight (kg) 3.3±0.1 3.3±0.1
Gestational age (weeks) 39.1±0.2 38.6±0.3
Weight loss (% of birth weight) 7.6±0.4* 5.9±0.5*
Parity (% nulliparae) 22 (67%) 6 (22%)
Male (% of all infants) 16 (48%) 13 (48%)
Caesarian section
(% of all infants)
31 (94%) 21 (78%)
All values are means ± standard error of the mean (SEM).
*p<0.05. There were no significant differences between BF and FF
infants in any of the other parameters.
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We investigated the relationships between stool production,
fecal fat excretion and jaundice in healthy BF and FF term
neonates. In contrast to previous studies, we found that BF
and FF infants had similar levels of jaundice and stool
production during the first postnatal days.
De Carvalho et al. reported a negative linear correlation
between neonatal stool production and serum bilirubin
concentrations [7]. In the present study, however, TcB
levels were neither related to cumulative stool production
(Fig. 4) nor to neonatal fecal fat excretion (Fig. 5). Many
factors have been implied to influence the severity of
neonatal jaundice, such as parity, weight loss, mode of
delivery, gestational age, and maternal characteristics such
as age and smoking. It needs to be realized, however, that
the various studies on these factors are not conclusive and
sometimes even contradictory [1, 6, 9, 23, 25, 30]. In our
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Fig. 1 Transcutaneous bilirubin levels measured in breast-fed (BF)
and formula-fed (FF) infants during the first postnatal days. Bilirubin
levels did not differ significantly between BF (n=33) and FF (n=27)
in any of the first 4 days after birth. Values represent means ± standard
error of the mean (SEM). No significant differences were found. Tc
Transcutaneous. [17.1 μmol/l unconjugated bilirubin (UCB) equals
1 mg/dl UCB]
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Fig. 2 Cumulative stool production in FF and BF infants during the
first 4 postnatal days In the first 4 postnatal days the total amount of
stool production did not significantly differ between BF (n=27) and
FF (n =21) infants. Values represent means ± SEM. Differences
between the two groups of infants were not statistically significant at
any of the days studied
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Fig. 3 Cumulative fecal fat excretion (in grams per day) in BF
(n=27) and FF infants (n=21) Cumulative fecal fat excretion in FF
infants was similar to that in BF infants during first 4 postnatal days.
Values represent means ± SEM. No significant differences were found
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Fig. 4 The relationship between transcutaneous (Tc) bilirubin levels
and cumulative stool production in the first postnatal days of BF and
FF term neonates. TcB levels in both BF and FF infants (n = 48) at
postnatal day 3 are not correlated with cumulative stool production
between post-partum day 0 and day 3 (R
2=0.0055 for BF, R
2=0.0004
for FF infants)
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and FF infants. We do not consider it likely, however, that
this could account for the similar degree of neonatal
jaundice in the two groups. A higher weight loss (possibly
due to decreased nutritional intake) was found in the BF
infants, and one could have expected higher bilirubin
concentrations in BF infants, what we did not observe.
We also did not consider it likely that the trancutaneous
analysis of bilirubin levels is responsible for the lack of
difference between BF and FF infants. In the range of
bilirubin values reported in the present study, the TcB
measurement is accurate, reproducible and comparable to
the standard of care laboratory tests, [4, 5, 28, 29]. We
considered the possibility that the relatively small number
of infants could mask possible differences between BF and
FF infants. However, De Carvalho et al. did find significant
differences with 40% fewer infants. It therefore seems
likely that the lack of difference in bilirubin levels between
the two groups of infants in our study cannot be attributed
to these various factors. The apparent discrepancy between
the present observations and the data reported previously by
De Carvalho et al. was further analyzed (Fig. 6). BF infants
in De Carvalho et al.’s study and in the present study
produced rather similar amounts of stool (estimated
difference of approx. 20% based on figures; original data
were not available; personal communication with M. De
Carvalho). FF infants in the present study, however,
produced profoundly lower levels of stools compared to
the FF infants reported by De Carvalho (cumulative stool
weight: 36 vs. 80 g at day 3, respectively). Since the results
of BF infants were similar, we consider it unlikely that
differences in the methodology of feces collection or
weighing could account for the results of the FF infants,
who were subjected to identical procedures. Rather, we
hypothesize that differences in the formulas used, and
therefore differences in intestinal (fat-)absorbability, may
play a role in the apparent discrepancy. Modernization of
formula-feeding may have led to improved absorbability
and correspondingly to lower fat malabsorption in FF
infants. Indeed, fecal fat excretion in FF infants is
approaching the levels of excretion in BF infants [27].
Upon requesting information concerning possible changes
in the composition of infant nutrition with a major supplier
in the Netherlands, Nutricia B.V., we learned that the
contribution of medium-chain triglycerides was increased in
1991 by 43% (from 14.3 to 20.5 g/100 g fatty acids). It is
well known that medium-chain triglycerides have a higher
absorbability than long(er) chain triglycerides. Detailed
information on fat content and composition of the formula
used in De Carvalho et al.’s study was not available.
Differencesinneonatalbilirubin levelsbetween BF and FF
infants have been described frequently in the past. More
recently, however, it has been questioned whether BF infants
in general have higher bilirubin levels. Bertini et al. measured
UCB ofmorethan2000terminfants inthe first postnataldays
and found that only a small subgroup of the BF infants had
significant hyperbilirubinemia, possibly related to fasting [3].
Our data are in accordance with those of Bertini et al. and,
together with results from other recent studies, indicate that
the extent of neonatal jaundice in the first postnatal days is
similar in FF and BF infants. The possible mechanism
underlying this phenomenon is unclear.
The neonatal TcB levels of the present study are similar
to previously reported average bilirubin levels in term
infants in the first postnatal days [8]. Peak bilirubin levels
are normally found on postnatal days 4 or 5 in term infants
[8]. Our own data indeed indicate that the bilirubin
concentrations level off at day 4 (Fig. 1). Due to the
standard release of mothers and neonates from the hospital
Fig. 6 Cumulative weight of stools in the first postnatal days in BF
and FF infants: a comparison of data from De Carvalho et al.’s 1985
study [7] and the present study. FF infants in the present study
produced less stool than the FF infants in De Carvalho et al.’s study.
In contrast, BF infants produced similar amounts of stool as those
studied in 1985
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Fig. 5 The relationship between TcB levels and cumulative fecal fat
excretion in the first postnatal days of BF and FF term neonates. TcB
levels in both BF and FF infants (n = 48) at postnatal day 3 are not
correlated with cumulative fecal fat excretion between day 0 and day 3
(r
2=0.019 for BF, r
2=0.065 for FF infants)
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until this time point.
In our study, the incidence of severe hyperbilirubinemia
requiring phototherapy was 1.6 %, which is low compared
to a known incidence of 5.1–10.5% [3, 24, 31]. This is
probably due to the exclusion of infants with a known high
risk of hyperbilirubinemia from the study. Our study
included a high number of infants born by caesarian section
who are known to have a decreased risk of hyperbiliru-
binemia. De Carvalho et al. reported somewhat higher
bilirubin levels in the first postnatal days, possibly due to a
high number of infants with forceps delivery [7].
In summary, we originally hypothesized that the differ-
ence in the extent of neonatal jaundice between FF and BF
infants was related to the efficacy of fat (mal)absorption.
However, the similarity in neonatal jaundice (and stool
production) observed in the present study provide an
indication for a “change in paradigm” with respect to the
effect of breast feeding on the exaggeration of neonatal
jaundice during the first postnatal days. It is tempting to
speculate that, in accordance with our hypothesis, the now
similar fecal fat excretion rates in BF and FF infants has led
to an equally high ability to capture UCB in the intestinal
lumen and prevent its enterohepatic circulation.
References
1. Adams JA, Hey DJ, Hall RT (1985) Incidence of hyper-
bilirubinemia in breast- vs. formula-fed infants. Clin Pediatr
24(2):69–73
2. Alonso EM, Whitington PF, Whitington SH, Rivard WA, Given G
(1991) Enterohepatic circulation of nonconjugated bilirubin in rats
fed with human milk. J Pediatr 118(3):425–430
3. Bertini G, Dani C, Tronchin M, Rubaltelli FF (2001) Is
breastfeeding really favoring early neonatal jaundice? Pediatrics
107(3):E41
4. Bertini G, Rubaltelli FF (2002) Non-invasive bilirubinometry in
neonatal jaundice. Semin Neonatol 7(2):129–133
5. Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson
LH (2000) Noninvasive measurement of total serum bilirubin in a
multiracial predischarge newborn population to assess the risk of
severe hyperbilirubinemia. Pediatrics 106(2):E17
6. Bracci R, Buonocore G, Garosi G, Bruchi S, Berni S (1989)
Epidemiologic study of neonatal jaundice. A survey of contrib-
uting factors. Acta Paediatr Scand Suppl 360:87–92
7. De Carvalho M, Robertson S, Klaus M (1985) Fecal bilirubin
excretion and serum bilirubin concentrations in breast-fed and
bottle-fed infants. J Pediatr 107(5):786–790
8. Fanaroff M (2002) Neonatal jaundice and liver disease. In:
Neonatal and perinatal medicine: diseases of the fetus and infant.
Mosby, St. Louis, pp 1315–1317
9. Gale R, Seidman DS, Dollberg S, Stevenson DK (1990)
Epidemiology of neonatal jaundice in the Jerusalem population.
J Pediatr Gastroenterol Nutr 10(1):82–86
10. Gartner LM, Herschel M (2001) Jaundice and breastfeeding.
Pediatr Clin North Am 48(2):389–399
11. Gartner LM, Lee KS, Moscioni AD (1983) Effect of milk feeding
on intestinal bilirubin absorption in the rat. J Pediatr 103(3):
464–471
12. Gourley GR (2002) Breast-feeding, neonatal jaundice and
kernicterus. Semin Neonatol 7(2):135–141
13. Gourley GR, Arend RA (1986) beta-Glucuronidase and hyper-
bilirubinaemia in breast-fed and formula-fed babies. Lancet 1
(8482):644–646
14. Gourley GR, Kreamer B, Arend R (1992) The effect of diet on
feces and jaundice during the first 3 weeks of life. Gastroenter-
ology 103(2):660–667
15. Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ (2005)
Effective oral treatment of unconjugated hyperbilirubinemia in
Gunn rats. Hepatology 41(3):526–534
16. Hintz SR, Gaylord TD, Oh W, Fanaroff AA, Mele L, Stevenson
DK (2001) Serum bilirubin levels at 72 hours by selected
characteristics in breastfed and formula-fed term infants delivered
by cesarean section. Acta Paediatr 90(7):776–781
17. Ince Z, Coban A, Peker I, Can G (1995) Breast milk beta-
glucuronidase and prolonged jaundice in the neonate. Acta
Paediatr 84(3):237–239
18. Jakobs BS, Volmer M, Swinkels DW, Hofs MT, Donkervoort S,
Joosting MM, Wolthers BG, de Peinder P, Voorbij HA (2000)
New method for faecal fat determination by mid-infrared
spectroscopy, using a transmission cell: an improvement in
standardization. Ann Clin Biochem 37(Pt 3):343–349
19. Johnson CA, Lieberman B, Hassanein RE (1985) The relationship
of breast feeding to third-day bilirubin levels. J Fam Pract 20
(2):147–152
20. Kotal P, Van der Veere CN, Sinaasappel M, Elferink RO, Vitek L,
Brodanova M, Jansen PL, Fevery J (1997) Intestinal excretion of
unconjugated bilirubin in man and rats with inherited unconju-
gated hyperbilirubinemia. Pediatr Res 42(2):195–200
21. Lester R, Schmid R (1963) Intestinal absorption of bile pigments.
I. The enterohepatic circulation of bilirubin in the rat. J Clin Invest
42:736–746
22. Lester R, Schmid R (1963) Intestinal absorption of bile pigments.
II. Bilirubin absorption in man. N Engl J Med 269:178–182
23. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG,
Ryan KJ (1985) Epidemiology of neonatal hyperbilirubinemia.
Pediatrics 75(4):770–774
24. Maisels MJ, Gifford K (1986) Normal serum bilirubin levels in the
newborn and the effect of breast-feeding. Pediatrics 78(5):837–
843
25. Maisels MJ, Gifford K, Antle CE, Leib GR (1988) Jaundice in the
healthy newborn infant: a new approach to an old problem.
Pediatrics 81(4):505–511
26. Nishioka T, Hafkamp AM, Havinga R, vn Lierop PP, Velvis H,
Verkade HJ (2003) Orlistat treatment increases fecal bilirubin
excretion and decreases plasma bilirubin concentrations in hyper-
bilirubinemic Gunn rats. J Pediatr 143(3):327–334
27. Rings EH, Minich DM, Vonk RJ, Stellaard F, Fetter WP,
Verkade HJ (2002) Functional development of fat absorption in
term and preterm neonates strongly correlates with ability to
absorb long-chain fatty acids from intestinal lumen. Pediatr Res
51(1):57–63
28. Robertson A, Kazmierczak S, Vos P (2002) Improved transcu-
taneous bilirubinometry: comparison of SpectR(X) BiliCheck
and Minolta Jaundice Meter JM-102 for estimating total serum
bilirubin in a normal newborn population. J Perinatol 22(1):
12–14
29. Rubaltelli FF, Gourley GR, Loskamp N, Modi N, Roth-Kleiner M,
Sender A, Vert P (2001) Transcutaneous bilirubin measurement: a
multicenter evaluation of a new device. Pediatrics 107(6):
1264–1271
506 Eur J Pediatr (2008) 167:501–50730. Saigal S, Lunyk O, Bennett KJ, Patterson MC (1982) Serum
bilirubin levels in breast- and formula-fed infants in the first
5 days of life. Can Med Assoc J 127(10):985–989
31. Sarici SU, Serdar MA, Korkmaz A, Erdem G, Oran O, Tekinalp
G, Yurdakok M, Yigit S (2004) Incidence, course, and prediction
of hyperbilirubinemia in near-term and term newborns. Pediatrics
113(4):775–780
32. Schneider AP (1986) Breast milk jaundice in the newborn. A real
entity. JAMA 255(23):3270–3274
33. Verkade HJ (2002) A novel hypothesis on the pathophysiology of
neonatal jaundice. J Pediatr 141(4):594–595
34. Verkade HJ, Hoving EB, Muskiet FA, Martini IA, Jansen G, Okken
A, Vonk RJ, Bijleveld CM (1991) Fat absorption in neonates:
comparison of long-chain-fatty-acid and triglyceride compositions
of formula, feces, and blood. Am J Clin Nutr 53(3):643–651
35. Zucker SD,GoesslingW,HoppinAG(1999) Unconjugatedbilirubin
exhibits spontaneous diffusion through model lipid bilayers and
native hepatocyte membranes. J Biol Chem 274(16):10852–10862
Eur J Pediatr (2008) 167:501–507 507